Skip to Main Content

Paper Details

Use of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 [TIMP2]â¿¢[IGFBP7] as an AKI risk screening tool to manage patients in the real-world setting.
J Crit Care
15
2020
Author NameAffiliation
Sandra L Kane-GillUniversity of Pittsburgh School of Pharmacy, Department of Pharmacy and Therapeutics, Department of Pharmacy, United States of America Center for Critical Care Nephrology, University of Pittsburgh
Raghavan MuruganCenter for Critical Care Nephrology, University of Pittsburgh
John A KellumCenter for Critical Care Nephrology, University of Pittsburgh
  • 1 - 3

Datasets

Release 1.2